|
CONCOMITANT USE PRODUCE PERSISTENTLY ELEVATED PLASMA CONCENTRATIONS OF CYCLOSPORINE RESULTING IN ELEVATED CREATININE, DESPITE REDUCTION IN DOSE OF CYCLOSPORINE
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
DILTIAZEM INHIBITS CYTOCHROME P450 3A ENZYME AND CO-ADMINISTRATION MAY RESULT IN INCREASED CYCLOSPORINE CONCENTRATIONS ; A REDUCTION IN CYCLOSPORINE DOSE MAY BE REQUIRED, ESPECIALLY IN RENAL AND CARDIAC TRANSPLANT RECIPIENTS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
CHLOROQUINE INCREASES PLASMA CONCENTRATION OF CYCLOSPORINE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF CYCLOSPORINE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF CYCLOSPORINE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF CYCLOSPORINE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF CYCLOSPORINE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF CYCLOSPORINE
|
PHENYTOIN ENHANCES THE DRUG METABOLISM HENCE DECREASED SERUM LEVELS HAVE BEEN OBSERVED
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
AZITHROMYCIN OR MACROLIDES INCREASE ABSORPTION OF THE DRUG
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
DIGOXIN CONCENTRATION IS INCREASED
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
TRANSIENT ELEVATIONS IN SERUM CREATININE
|
TRANSIENT ELEVATIONS IN SERUM CREATININE
|
TRANSIENT ELEVATIONS IN SERUM CREATININE
|
TRANSIENT ELEVATIONS IN SERUM CREATININE
|
TRANSIENT ELEVATIONS IN SERUM CREATININE
|
TRANSIENT ELEVATIONS IN SERUM CREATININE
|
TRANSIENT ELEVATIONS IN SERUM CREATININE
|
TRANSIENT ELEVATIONS IN SERUM CREATININE
|
TRANSIENT ELEVATIONS IN SERUM CREATININE
|
TRANSIENT ELEVATIONS IN SERUM CREATININE
|
TRANSIENT ELEVATIONS IN SERUM CREATININE
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
HIGH LEVELS OF HMG-COA REDUCTASE INHIBITORY ACTIVITY IN PLASMA;LOVASTATIN IS METABOLIZED BY CYP3A4 ISOENZYME,CERTAIN AGENTS, SHARE THIS METABOLIC PATHWAY AND CAN RAISE THE PLASMA LEVELS OF LOVASTATIN & MAY INCREASE THE RISK OF MYOPATHY
|
HIGH LEVELS OF HMG-COA REDUCTASE INHIBITORY ACTIVITY IN PLASMA;LOVASTATIN IS METABOLIZED BY CYP3A4 ISOENZYME,CERTAIN AGENTS, SHARE THIS METABOLIC PATHWAY AND CAN RAISE THE PLASMA LEVELS OF LOVASTATIN & MAY INCREASE THE RISK OF MYOPATHY
|
HIGH LEVELS OF HMG-COA REDUCTASE INHIBITORY ACTIVITY IN PLASMA;LOVASTATIN IS METABOLIZED BY CYP3A4 ISOENZYME,CERTAIN AGENTS, SHARE THIS METABOLIC PATHWAY AND CAN RAISE THE PLASMA LEVELS OF LOVASTATIN & MAY INCREASE THE RISK OF MYOPATHY
|
HIGH LEVELS OF HMG-COA REDUCTASE INHIBITORY ACTIVITY IN PLASMA;LOVASTATIN IS METABOLIZED BY CYP3A4 ISOENZYME,CERTAIN AGENTS, SHARE THIS METABOLIC PATHWAY AND CAN RAISE THE PLASMA LEVELS OF LOVASTATIN & MAY INCREASE THE RISK OF MYOPATHY
|
CYCLOSPORINE SERUM LEVELS ARE REDUCED BY THE DRUG
|
CYCLOSPORINE SERUM LEVELS ARE REDUCED BY THE DRUG
|
CYCLOSPORINE SERUM LEVELS ARE REDUCED BY THE DRUG
|
CYCLOSPORINE SERUM LEVELS ARE REDUCED BY THE DRUG
|
ALLOPURINOL REDUCES RENAL CLEARANCE OF THE DRUG SO THE DRUG DOSE SHOULD BE REDUCED TO 1/3 OR 1/4
|
CLOSTEBOL ACTIVITY IS ENHANCED BY THE DRUG SO INCREASED CHANCES OF TOXICITY
|
ARMODAFINIL MODERATELY INDUCES CYP3A ACTIVITY REDUCING PLASMA CONC OF OTHER DRUG, HENCE DOSE ADJUSTMENT IS NEEDED
|